非HIV马尔尼菲篮状菌病的研究进展

doi:10.19871/j.cnki.xfcrbzz.2022.02.018

摘要/Abstract

摘要： 马尔尼菲篮状菌（TM）是一种机会性致病菌,主要发生于HIV感染者,而近年来关于非HIV患者的报道逐年增多,与机体的免疫功能低下有关。儿童免疫功能低下的主要因素为各种原发性免疫缺陷,成人免疫功能低下的主要因素则为抗γ干扰素抗体综合征、自身免疫性疾病、激素和/或免疫抑制剂使用、恶性肿瘤、糖尿病等。非HIV马尔尼菲篮状菌病患者的临床表现以播散型感染最为常见,可能合并其他机会性感染、继发噬血细胞综合征。HIV与非HIV马尔尼菲篮状菌病患者的临床表现及预后存在一定差异,且目前尚无关于非HIV马尔尼菲篮状菌病的标准治疗方案。本研究对非HIV马尔尼菲篮状菌病的流行病学、免疫功能低下因素、临床表现、诊断、治疗和预后进行综述。

关键词: 马尔尼菲篮状菌病, 免疫功能低下, 临床表现, 治疗

Abstract: Talaromyces marneffei is an opportunistic pathogen, which mainly occurs in human immunodeficiency virus (HIV)-infected patients. Whereas, non-HIV Talaromycosis patients increased in recent years which was related to the compromised immune conditions of hosts. The most common underlying diseases in children were various primary immunodeficiency diseases. The most common underlying diseases in adults were anti-interferon-gamma autoantibody (AIGA) syndrome, autoimmune diseases, glucocorticoid and/or immunosuppressive therapy, malignancy, diabetes and so on. Most non-HIV Talaromycosis patients occurred disseminated infection, and might coinfected with other opportunity pathogens and had secondary hemophagocytic lymphohistiocytosis. The clinical manifestations and prognosis of non-HIV Talaromycosis patients were different from that of HIV-infected patients. Herein, we reviewed the epidemiology, immunodeficiency, clinical manifestations, diagnosis, treatment and prognosis of non-HIV Talaromycosis.

Key words: Talaromycosis, Immunodeficiency, Clinical manifestations, Treatment

黄丽萍, 陆艾丽, 彭劼. 非HIV马尔尼菲篮状菌病的研究进展[J]. 新发传染病电子杂志, 2022, 7(2): 89-94.

Huang Liping, Lu Aili, Peng Jie. Progress on Talaromycosis in non-HIV-infected patients[J]. Electronic Journal of Emerging Infectious Diseases, 2022, 7(2): 89-94.

参考文献

[1] LI XQ, YANG YB, ZHANG X, et al.Isolation of Penicillium marneffei from soil and wild rodents in Guangdong, SE China[J]. Mycopathologia, 2011,172(6):447-551.
[2] HUANG XW, HE GH, LU S, et al.Role of Rhizomys pruinosus as a natural animal host of Penicillium marneffei in Guangdong, China[J]. Microb Biotechnol,2015,8(4):659-664.
[3] CHAIWUN B, VANITTANAKOM N, JIVIRIYAWAT Y, et al.Investigation of dogs as a reservoir of Penicillium marneffei in northern Thailand[J]. Int J Infect Dis, 2011, 15(4):e236-e239.
[4] LI YH, LUO HL, FAN JT, et al.Genomic analysis provides insights into the transmission and pathogenicity of Talaromyces marneffei[J]. Fungal Genet Biol, 2019, 130:54-61.
[5] ZHAO YK, LIU JY, LIU JH, et al.Recurrent Talaromyces marneffei Infection Presenting with Intestinal Obstruction in a Patient with Systemic Lupus Erythematosus[J]. Mycopathologia, 2020, 185(4):717-726.
[6] LU YS, SHI Q, YU J.Drug-related talaromycosis: A case report[J]. Int J Immunopathol Pharmacol, 2020,34:1-6.
[7] WEI JS, QIU Y, ZENG W, et al.Talaromyces marneffei Infection in Systemic Lupus Erythematosus Patients: Report of Two Cases and Review of the Literature[J]. Infect Drug Resist, 2020, 13:3811-3816.
[8] DISALVO AF, FICKLING AM, AJELLO L.Infection caused by Penicillium marneffei: description of first natural infection in man[J]. Am J Clin Pathol,1973,60(2):259-263.
[9] PETO TE, BULL R, MILLARD PR, et al.Systemic mycosis due to Penicillium marneffei in a patient with antibody to human immunodeficiency virus[J]. J Infect, 1988, 16(3):285-290.
[10] CHAN JF, LAU SK, YUEN KY, et al.Talaromyces (Penicillium) marneffei infection in non-HIV-infected patients[J]. Emerg Microbes Infect,2016,5(3):e19-e27.
[11] VERGIDIS P, RAO A, MOORE CB, et al.Talaromycosis in a renal transplant recipient returning from South China[J]. Transpl Infect Dis, 2021, 23(1):e13447-e13451.
[12] STATHAKIS A, LIM KP, BOAN P, et al.Penicillium marneffei infection in a lung transplant recipient[J]. Transpl Infect Dis, 2015, 17(3):429-434.
[13] CHARIYALERTSAK S, SIRISANTHANA T, SUPPARATPINYO K, et al.Seasonal variation of disseminated Penicillium marneffei infections in northern Thailand: a clue to the reservoir?[J]. J Infect Dis, 1996, 173(6):1490-1493.
[14] QIU Y, FENG X, ZENG W, et al.Immunodeficiency Disease Spectrum in HIV-Negative Individuals with Talaromycosis[J]. J Clin Immunol, 2021, 41(1):221-223.
[15] LEE PP, CHAN KW, LEE TL, et al.Penicilliosis in children without HIV infection--are they immunodeficient?[J]. Clin Infect Dis, 2012, 54(2):e8-e19.
[16] PAN ML, QIU Y, ZENG W, et al.Talaromycosis-Associated Secondary Hemophagocytic Lymphohistiocytosis in Nine Human Immunodeficiency Virus-Negative Patients: A Multicenter Retrospective Study[J]. Infect Drug Resist, 2019, 12:3807-3816.
[17] GUO J, LI BK, LI TM, et al.Characteristics and Prognosis of Talaromyces marneffei Infection in Non-HIV-Infected Children in Southern China[J]. Mycopathologia, 2019, 184(6):735-745.
[18] LEE PP, LAO-ARAYA M, YANG J, et al.Application of Flow Cytometry in the Diagnostics Pipeline of Primary Immunodeficiencies Underlying Disseminated Talaromyces marneffei Infection in HIV-Negative Children[J]. Front Immunol, 2019, 10:2189-2202.
[19] HÖFLICH C, SABAT R, ROSSEAU S, et al. Naturally occurring anti-IFN-gamma autoantibody and severe infections with Mycobacterium cheloneae and Burkholderia cocovenenans[J]. Blood, 2004, 103(2):673-675.
[20] AOKI A, SAKAGAMI T, YOSHIZAWA K, et al.Clinical Significance of Interferon-γ Neutralizing Autoantibodies Against Disseminated Nontuberculous Mycobacterial Disease[J]. Clin Infect Dis, 2018, 66(8):1239-1245.
[21] SHIH HP, DING JY, YEH CF, et al.Anti-interferon-γ autoantibody-associated immunodeficiency[J]. Curr Opin Immunol, 2021, 72:206-214.
[22] BROWNE SK, BURBELO PD, CHETCHOTISAKD P, et al.Adult-onset immunodeficiency in Thailand and Taiwan[J]. N Engl J Med, 2012, 367(8):725-734.
[23] QIU Y, HUANG J, LI Y, et al.Talaromyces marneffei and nontuberculous mycobacteria co-infection in HIV-negative patients[J]. Sci Rep, 2021, 11(1):16177-16186.
[24] SHIMA K, SAKAGAMI T, TANABE Y, et al.Novel assay to detect increased level of neutralizing anti-interferon gamma autoantibodies in non-tuberculous mycobacterial patients[J]. J Infect Chemother, 2014, 20(1):52-56.
[25] YOSHIZAWA K, AOKI A, SHIMA K, et al.Serum Anti-interferon-γ Autoantibody Titer as a Potential Biomarker of Disseminated Non-tuberculous Mycobacterial Infection[J]. J Clin Immunol, 2020, 40(2):399-405.
[26] GUO J, NING XQ, DING JY, et al.Anti-IFN-γ autoantibodies underlie disseminated Talaromyces marneffei infections[J]. J Exp Med, 2020, 217(12): e20190502.
[27] CHEN ZM, LI ZT, LI SQ, et al.Clinical findings of Talaromyces marneffei infection among patients with anti-interferon-γ immunodeficiency: a prospective cohort study[J]. BMC Infect Dis, 2021, 21(1):587.
[28] ANGKASEKWINAI N, SUPUTTAMONGKOL Y, PHOOMPOUNG P, et al.Clinical outcome and laboratory markers for predicting disease activity in patients with disseminated opportunistic infections associated with anti-interferon-γ autoantibodies[J]. PLoS One, 2019, 14(4):e0215581.
[29] CHI CY, CHU CC, LIU JP, et al.Anti-IFN-γ autoantibodies in adults with disseminated nontuberculous mycobacterial infections are associated with HLA-DRB1*16:02 and HLA-DQB1*05:02 and the reactivation of latent varicella-zoster virus infection[J]. Blood, 2013, 121(8):1357-1366.
[30] PITHUKPAKORN M, ROOTHUMNONG E, ANGKASEKWINAI N, et al.HLA-DRB1 and HLA-DQB1 Are Associated with Adult-Onset Immunodeficiency with Acquired Anti-Interferon-Gamma Autoantibodies[J]. PLoS One, 2015, 10(5):e0128481.
[31] Ku CL, Lin CH, Chang SW, et al. Anti-IFN-γ autoantibodies are strongly associated with HLA-DR*15:02/16:02 and HLA-DQ*05:01/05:02 across Southeast Asia[J]. J Allergy Clin Immunol, 2016, 137(3):945-948.e8.
[32] KRISNAWATI DI, LIU YC, LEE YJ, et al.Blockade Effects of Anti-Interferon-(IFN-) γ Autoantibodies on IFN-γ-Regulated Antimicrobial Immunity[J]. J Immunol Res, 2019, 2019:1629258.
[33] CHRUEWKAMLOW N, MAHASONGKRAM K, PATA S, et al.Immune Alterations in Patients with Anti-Interferon-γ Autoantibodies[J]. PLoS One, 2016, 11(1):e0145983.
[34] CHAWANSUNTATI K, RATTANATHAMMETHEE K, WIPASA J.Minireview: Insights into anti-interferon-γ autoantibodies[J]. Exp Biol Med, 2021, 246(7):790-795.
[35] LAO MX, ZHAN ZP, SU F, et al.Invasive mycoses in patients with connective tissue disease from Southern China: clinical features and associated factors[J]. Arthritis Res Ther, 2019, 21(1):71-80.
[36] WONGKAMHLA T, CHONGTRAKOOL P, JITMUANG A.A case report of Talaromyces marneffei Oro-pharyngo-laryngitis: a rare manifestation of Talaromycosis[J]. BMC Infect Dis, 2019, 19(1):1034-1039.
[37] HE LY, MEI X, LU S, et al.Talaromyces marneffei infection in non-HIV-infected patients in mainland China[J]. Mycoses, 2021, 64(10):1170-1176.
[38] QIU Y, LU DC, ZHANG JQ, et al.Treatment of Disseminated Talaromyces marneffei with Tracheal Infection: Two Case Reports[J]. Mycopathologia, 2015, 180(3-4):245-249.
[39] QIU Y, PAN MQ, ZHANG JQ, et al.Two Unusual Cases of Human Immunodeficiency Virus-Negative Patients with Talaromyces marneffei Infection[J]. Am J Trop Med Hyg, 2016, 95(2):426-430.
[40] 杨蓬, 刘萍, 李秋文, 等. 肺癌合并马尔尼菲蓝状菌病1例并文献复习[J/CD].新发传染病电子杂志, 2019, 4(03):169-172.
[41] CHENG D, DING XH.Rare misdiagnosed case of penicilliosis marneffei in an immunocompetent patient[J]. J Int Med Rs, 2020, 48(10):300060520959484.
[42] YU XM, MIAO KJ, ZHOU CS, et al.T. marneffei infection complications in an HIV-negative patient with pre-existing pulmonary sarcoidosis: a rare case report[J]. BMC Infect Dis, 2018, 18(1):390-394.
[43] SU SS, ZHANG SN, YE JR, et al.Disseminated Talaromyces marneffei And Mycobacterium avium Infection Accompanied Sweet's Syndrome In A Patient With Anti-Interferon-γ Autoantibodies: A Case Report[J]. Infect Drug Resist, 2019, 12:3189-3195.
[44] CHEN DH, CHANG CD, CHEN M, et al.Unusual disseminated Talaromyces marneffei infection mimicking lymphoma in a non-immunosuppressed patient in East China: a case report and review of the literature[J]. BMC Infect Dis, 2020, 20(1):800-807.
[45] WEI HY, LIANG WJ, LI B, et al.Clinical characteristics and risk factors of Talaromyces marneffei infection in human immunodeficiency virus-negative patients: A retrospective observational study[J]. World J Emerg Med, 2021, 12(4):281-286.
[46] QIU Y, ZHANG JQ, LIU GN, et al.Retrospective analysis of 14 cases of disseminated Penicillium marneffei infection with osteolytic lesions[J]. BMC Infect Dis, 2015, 15:47-53.
[47] PAN ML, HUANG J, QIU Y, et al. Assessment of Talaromyces Marneffei Infection of the Intestine in Three Patients and a Systematic Review of Case Reports[J]. Open Forum Infect Dis, 2020, 7(6):ofaa128.
[48] WANG DM, MA HL, TAN MQ, et al.Next-generation sequencing confirmed the diagnosis of isolated central nervous system infection caused by Talaromyces marneffei in an immunocompetent patient[J]. Chin Med J, 2020, 133(3):374-376.
[49] LE T, HUU CHI N, KIM CUC NT, et al.AIDS-associated Penicillium marneffei infection of the central nervous system[J]. Clin Infect Dis, 2010, 51(12):1458-1462.
[50] LI YY, DONG RJ, SHRESTHA S, et al.AIDS-associated Talaromyces marneffei central nervous system infection in patients of southwestern China[J]. AIDS Res Ther, 2020, 17(1):26-34.
[51] JIN WH, LIU JH, CHEN K, et al.Coinfection by Talaromyces marneffei and Mycobacterium abscessus in a human immunodeficiency virus-negative patient with anti-interferon-γ autoantibody: a case report[J]. J Int Med Res, 2021, 49(1):300060520976471.
[52] HE SS, LV DQ, XU YZ, et al.Concurrent infection with Talaromyces marneffei and Cryptococcus neoformans in a patient without HIV infection[J]. Exp Ther Med, 2020, 19(1):160-164.
[53] CHAN JF, CHAN TS, GILL H, et al.Disseminated Infections with Talaromyces marneffei in Non-AIDS Patients Given Monoclonal Antibodies against CD20 and Kinase Inhibitors[J]. Emerg Infect Dis, 2015, 21(7):1101-1106.
[54] 郑祎,王辉.艾滋病合并马尔尼菲篮状菌感染的诊治临床研究进展[J/CD].新发传染病电子杂志,2021, 6(2):151-154.
[55] KAWILA R, CHAIWARITH R, SUPPARATPINYO K.Clinical and laboratory characteristics of penicilliosis marneffei among patients with and without HIV infection in Northern Thailand: a retrospective study[J]. BMC Infect Dis, 2013, 13:464-468.
[56] SHEN Q, SHENG L, ZHANG J, et al.Analysis of clinical characteristics and prognosis of talaromycosis (with or without human immunodeficiency virus) from a non-endemic area: a retrospective study[J]. Infection, 2021, 5:1-10.
[57] 曹静, 谢浩俊, 成卫英, 等. HIV阴性与HIV阳性的马尔尼菲蓝状菌病患者临床特点分析[J].中国皮肤性病学杂志, 2018, 32(10):1158-1162.
[58] 张建全,杨美玲,钟小宁,等.人免疫缺陷病毒抗体阴性与阳性者播散性马尔尼菲青霉菌病的临床及实验室特征[J].中华结核和呼吸杂志, 2008,21(10):740-746.
[59] WONG SS, WONG KH, HUI WT, et al.Differences in clinical and laboratory diagnostic characteristics of penicilliosis marneffei in human immunodeficiency virus (HIV)-and non-HIV-infected patients[J]. J Clin Microbiol, 2001, 39(12):4535-4540.
[60] LI HR, CAI SX, CHEN YS, et al.Comparison of Talaromyces marneffei Infection in Human Immunodeficiency Virus-positive and Human Immunodeficiency Virus-negative Patients from Fujian, China[J]. Chin Med J (Engl), 2016, 129(9):1059-1065.
[61] QIN YY, HUANG XJ, CHEN H, et al.Burden of Talaromyces marneffei infection in people living with HIV/AIDS in Asia during ART era: a systematic review and meta-analysis[J]. BMC Infect Dis, 2020, 20(1):551-564.
[62] MASUR H, BROOKS JT, BENSON CA, et al.Prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Updated Guidelines from the Centers for Disease Control and Prevention, National Institutes of Health, and HIV Medicine Association of the Infectious Diseases Society of America[J]. Clin Infect Dis, 2014, 58(9):1308-1311.
[63] TSANG CC, TENG JLL, LAU SKP, et al.Rapid Genomic Diagnosis of Fungal Infections in the Age of Next-Generation Sequencing[J]. J Fungi, 2021, 7(8):636-650.
[64] CHEN QH, QIU Y, ZENG W, et al.Metagenomic next-generation sequencing for the early diagnosis of talaromycosis in HIV-uninfected patients: five cases report[J]. BMC Infect Dis, 2021, 21(1):865-872.
[65] THU NTM, CHAN JFW, LY VT, et al.Superiority of a Novel Mp1p Antigen Detection Enzyme Immunoassay Compared to Standard BACTEC Blood Culture in the Diagnosis of Talaromycosis[J]. Clin Infect Dis, 2021, 73(2):330-336.
[66] 韩静, 蒋忠胜, 王刚, 等. 广西人类免疫缺陷病毒感染者/艾滋病患者合并马尔尼菲篮状菌感染的特征及Mp1p抗原快速筛检的研究[J].微生物与感染, 2021, 16(1):19-25.
[67] 李凌华, 肖赛银, 何艳, 等. 血清Mp1p抗原检测对艾滋病合并马尔尼菲蓝状菌病的诊断价值[J].中华传染病杂志, 2017, 35(3):157-160.
[68] LEI HL, LI LH, CHEN WS, et al.Susceptibility profile of echinocandins, azoles and amphotericin B against yeast phase of Talaromyces marneffei isolated from HIV-infected patients in Guangdong, China[J]. Eur J Clin Microbiol Infect Dis, 2018, 37(6):1099-1102.
[69] BOON-LONG J, MEKHA N, POONWAN N, et al.In vitro antifungal activity of the new triazole D0870 against Penicillium marneffei compared with that of amphotericin B, fluconazole, itraconazole, miconazole and flucytosine[J]. Mycoses, 1996, 39(11-12):453-456.
[70] OUYANG Y, CAI S, LIANG H, et al.Administration of Voriconazole in Disseminated Talaromyces (Penicillium) Marneffei Infection: A Retrospective Study[J]. Mycopathologia, 2017, 182(5-6):569-575.
[71] LANG Q, CHUGHTAI A, KONG WF, et al.Case Report: Successful Treatment of Pulmonary Talaromyces marneffei Infection with Posaconazole in a Renal Transplant Recipient[J]. Am J Trop Med Hyg, 2020, 104(2):744-747.
[72] ZHANG J, HUANG XY, ZHANG X, et al.Coinfection of disseminated Talaromyces marneffei and Mycobacteria kansasii in a patient with papillary thyroid cancer: A case report[J]. Medicine, 2017, 96(52):e9072-e9076.